Advertisement

BMC Nephrology

, 19:341 | Cite as

Peritoneal dialysis-associated infection caused by Mycobacterium abscessus: a case report

  • Ryuichi Yoshimura
  • Miharu Kawanishi
  • Shungo Fujii
  • Aska Yamauchi
  • Kentaro Takase
  • Kaori Yoshikane
  • Masahiro Egawa
  • Hiroaki Shiina
  • Takafumi Ito
Open Access
Case report
Part of the following topical collections:
  1. Case Reports

Abstract

Background

Peritoneal dialysis (PD)-associated infection caused by Mycobacterium spp. is rare. Mycobacterium abscessus is one of the most resistant acid-fast bacteria, and treatment is also the most difficult and refractory. Thus, we report a case of PD-associated peritonitis caused by Mycobacterium abscessus that was difficult to treat and led to PD failure.

Case presentation

We recently encountered a 56-year-old man who developed PD-associated infection. We initially suspected exit-site infection (ESI) and tunnel infection (TI) caused by methicillin-resistant coagulase-negative Staphylococcus. However, antibiotic therapy did not provide any significant improvement. Thus, we performed simultaneous removal and reinsertion of a PD catheter at a new exit site. The patient subsequently developed peritonitis and Mycobacterium abscessus was detected in the peritoneal effluent. Thus, the reinserted catheter was removed, hemodialysis was started, and the patient was eventually discharged.

Conclusions

In cases of refractory ESI or TI, it is important to consider non-tuberculous mycobacteria as the potentially causative organism. Even if acid-fast bacterial staining is negative or not performed, detection of Gram-negative bacillus may lead to suspicion and early identification of Mycobacterium spp. In PD-associated infection by Mycobacterium abscessus, catheter removal is necessary in many cases. Simultaneous removal and reinsertion of the catheter is not recommended, even in cases of ESI or TI. Reinsertion should only be attempted after complete resolution of peritoneal symptoms. After removal of the catheter, careful follow-up is necessary, paying attention to complications such as wound infection, peritonitis, and ileus. In addition, the selection and treatment period of antibiotics in PD-associated infection by Mycobacterium abscessus remains unclear, and it is an important topic for future discussion.

Keywords

Peritoneal dialysis Infection Mycobacterium abscessus Peritonitis 

Abbreviations

ATS/IDSA

American Thoracic Society/Infectious Diseases Society of America

CAM

Clarithromycin

CRP

C-reactive protein

ESI

Exit-site infection

GPR

Gram-positive rod

HD

Hemodialysis

ISPD

International Society for Peritoneal Dialysis

MRCNS

Methicillin-resistant coagulase-negative Staphylococcus

NTM

Non-tuberculous mycobacteria

PD

Peritoneal dialysis

RGNTM

Ruyon classification group IV of rapidly-growing mycobacteria

TI

Tunnel infection

Background

Peritoneal dialysis (PD) is associated with various infectious complications, such as exit-site infection (ESI), tunnel infection (TI), and peritonitis. Various organisms can cause ESI and TI, such as Staphylococcus aureus and Pseudomonas aeruginosa, which can frequently lead to peritonitis. Thus, these infections must be treated aggressively [1, 2].

Reports of peritonitis caused by non-tuberculous mycobacteria (NTM) are relatively rare, but are becoming more common [3]. More than 50% of the isolates are rapidly growing species, such as Mycobacterium fortuitum and M. chelonae [4], which are often detected after 3–5 days during routine bacteriological cultures. There is no well-established treatment for NTM-related peritonitis, and personalized treatment should be guided by susceptibility testing [5]. Catheter removal is usually necessary, and experience with non-removal is limited [4, 6, 7]. Unfortunately, most cases develop refractory peritonitis, despite long-term treatment, which ultimately causes PD failure. Thus, we report a case of PD-associated peritonitis caused by M. abscessus that was difficult to treat and led to PD failure.

Case presentation

A 56-year-old Japanese man with end-stage renal disease secondary to diabetic nephropathy visited our hospital because of abdominal pain and pus discharge from the exit site of a PD catheter. He had redness around the exit site and tenderness at the subcutaneous tunnel. The dialysis effluent was not cloudy and the effluent cell count was < 100/μL. Thus, we performed pus swab culture based on a suspicion of ESI and TI. Treatment was started using intravenous vancomycin (1.5 g/day), oral minocycline (200 mg/day), and topical gentamicin ointment, because the patient had a history of ESI caused by methicillin-resistant coagulase-negative Staphylococcus (MRCNS).

The patient was admitted to our hospital 3 days later, with the following vital signs: blood pressure of 165/104 mmHg, pulse of 86 bpm, and temperature of 36.7 °C. A physical examination revealed continued pus discharge from the exit site, as well as redness and swelling of the surrounding skin (Fig. 1). No rebound tenderness or muscle guarding were observed. A complete blood count from the admission revealed a white blood cell count of 8390/μL, a red blood cell count of 380 × 104/μL, a hemoglobin level of 10.1 g/dL, and a platelet count of 21.4 × 104/μL. The blood test results revealed an albumin level of 2.9 g/dL, a blood urea nitrogen level of 54.3 mg/dL, a creatinine level of 13.95 mg/dL, and a C-reactive protein (CRP) level of 0.09 mg/dL. The white cell count in the dialysis effluent was 7/μL (mononuclear cells: 6/μL, polymorphonuclear cells: 1/μL), and the pus culture revealed the presence of MRCNS.
Fig. 1

The catheter exit site on the day of admission. Redness and swelling are clearly visible around the catheter exit site

We continued to suspect that the ESI and TI were caused by MRCNS, and continued treatment using intravenous vancomycin (Fig. 2). However, abdominal computed tomography on day 7 revealed an increased density of fatty tissue around the PD catheter (Fig. 3 a, b). Thus, we performed simultaneous removal and reinsertion of the PD catheter at a new exit site, based on the refractory ESI and TI in the absence of peritonitis. The PD was re-started on day 12, although evaluation of the dialysis effluent on day 15 revealed that the white cell count had increased to 631/μL (mononuclear cells: 455/μL, polymorphonuclear cells: 176/μL), which supported a diagnosis of peritonitis. Negative results were obtained from Gram staining and acid-fast staining of the dialysis effluent. The dialysis effluent was then cultured in aerobic, anaerobic, and Ogawa media. Treatment was switched to intravenous meropenem (0.5 g/day) and intraperitoneal amikacin (2 mg/kg/day). On day 23, we observed a rise in the CRP level (10.1 mg/dL) and the number of white cells in the dialysis effluent (4126/μL). Therefore, the patient was converted to hemodialysis (HD) on day 24.
Fig. 2

The patient’s course from admission to discharge. AMK: amikacin, CAM: clarithromycin, CRP: C-reactive protein, HD: hemodialysis, IPM: imipenem, LZD: linezolid, M. abscessus: Mycobacterium abscessus, MEPM: meropenem, PD: peritoneal dialysis, p.o.: oral administration, TDM: therapeutic drug monitoring, VCM: vancomycin

Fig. 3

Radiological findings. On day 7, abdominal computed tomography revealed an increased density of fatty tissue around the PD catheter (arrows in a, b). On day 30, wound dehiscence was observed at the original exit site, with increased density of fatty tissue around the new catheter (arrows in c, d). On day 101, intestinal dilation was observed (e, f)

On day 29, gram-positive rods (GPR) were found in the aerobic culture of the dialysis effluent from day 15. These bacilli were sensitive to imipenem but resistant to meropenem and amikacin. On day 30, we noticed growth of acid-fast bacilli in Ogawa medium. The GPR from the aerobic culture were identified as M. abscessus on day 33. M. abscessus was also detected in cultures of the dialysis effluents from days 20 and 28. After switching the treatment from meropenem to imipenem, the CRP levels decreased. However, ESI and TI persisted at the reinserted catheter and wound dehiscence was detected at the old exit site (Fig. 3 c, d). Thus, the second catheter was removed on day 37, and the patient’s condition subsequently improved. Additional susceptibility testing revealed that the M. abscessus was sensitive to clarithromycin, and oral clarithromycin was started after 4 weeks of treatment using imipenem. Cultures of the catheter tip and intraoperative ascites fluid revealed positive results for M. abscessus. In addition, pathological findings at the original exit site revealed granulomatous dermatitis and a positive result during acid-fast staining. M. abscessus was detected in the wound cultures until day 58, although negative results were observed thereafter. On day 101, the patient developed nausea and vomiting, and computed tomography revealed intestinal dilation (Fig. 3 e, f). On day 103, the patient underwent laparoscopic adhesiolysis surgery because of adhesive ileus, and the intraoperative findings revealed adhesion of the intestinal tract near the abdominal wall site where the catheter had been placed. There were no findings of encapsulating peritoneal sclerosis, and M. abscessus was not detected during culture of the intraoperative ascites specimen. The patient was discharged on day 115, completed 6 months of treatment using clarithromycin monotherapy, and did not develop infection or ileus recurrence during the next 2 years.

Discussion and conclusions

M. abscessus belongs to the Ruyon classification group IV of rapidly-growing mycobacteria (RGNTM), which often provide positive results on routine bacteriologic cultures within 7 days. Although M. abscessus was previously classified as an M. chelonae subspecies, it was reclassified as an individual species in 1992 [8]. This organism is ubiquitous in soil and water, and commonly causes skin, soft tissue, bone, and respiratory infections.

Renaud et al. reported that RGNTM infections accounted for 3% of all culture-positive ESI and PD peritonitis cases [6]. Thus, RGNTM are a rare cause of PD-associated infections. Furthermore, among 57 cases of PD-associated NTM peritonitis, the most prevalent organism was M. fortinum (38.6%), which was followed by M. chelonae (14.0%), M. avium complex (10.5%), and M. abscessus (8.8%) [4]. Between 1998 and 2017, there have been 28 reported cases of PD-associated infection caused by M. abscessus [6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], and their characteristics are summarized in Table 1. The reported cases included 16 males and 12 females with a median age of 59 years (range: 14–89). Twenty-one cases (75.0%) involved ESI or TI at the beginning of treatment, which were thought to be para-catheter infections. However, 7 cases (25.0%) involved peritonitis without ESI or TI, which were thought to be transcatheter infections. The large proportion of para-catheter infections may be because mycobacteria are susceptible to heat and ultraviolet light, but can be resistant to disinfectants because they have large amounts of lipids in the cell wall, which can render benzalkonium chloride and chlorhexidine gluconate ineffective. The International Society for Peritoneal Dialysis (ISPD) guidelines recommend daily application of antibiotic cream or ointment to the catheter exit site, because it could prevent ESI caused by Staphylococcus aureus and Pseudomonas species [5]. However, extensive use of gentamicin ointment for ESIs may predispose patients to NTM infections of the exit site [13, 19]. In the present case, the patient had worked in a forest several times, and had used benzalkonium chloride to clean the exit site, which may have increased the risk of NTM infection.
Table 1

Comparison of the present case with previously reported PD-associated infections caused by Mycobacterium abscessus

Reference

Year

Duration of PD

Cause of ESRD, Underlying disease

Infection type at initial treatment

Surgical intervention

Clinical outcome

Antibiotics (duration)

The present case

2017

3 months

DMN

ESI, TI

Simultaneous catheter removal and reinsertion

Removed the reinserted catheter because of developing peritonitis, and converted to HD

CAM (6 months), IPM (4 weeks)

9

2017

12 months

nephrolithiasis

ESI

Simultaneous catheter removal and reinsertion

Removed the reinserted catheter because of prolonged ESI, and converted to HD

CAM, IPM, TGC (N/A)

10

2017

6 months

DMN

ESI

Catheter removal

Paliative care

CAM (44 days), AMK (25 days), IPM (25 days), FRPM (19 days)

11

2015

96 months

N/A

ESI, peritonitis

Catheter removal

Converted to HD, and died after 8 months because of renal hemorrhage and retroperitoneal infection

CAM (165 days), AMK (68 days), MEPM (165 days), LVFX (111 days)

11

2015

70 months

DMN

TI, peritonitis

Catheter removal

Converted to HD

CAM (234 days), AMK (50 days), IPM (70 days), CPFX (217 days), DOXY (180 days)

12

2013

12 months

Herb related

ESI, TI

Debridement Continued PD without catheter removal

Continued PD

CAM (2 months), CPFX (2 months), RFP (2 months)

7

2013

N/A

N/A

peritonitis

Catheter removal

Converted to HD, and died after 5 months because of peritoneal sclerosis

CEZ, GM (N/A)

7

2013

N/A

N/A

peritonitis

Catheter removal

Converted to HD

AMK, CFX, VCM, GM, MFIPC (N/A)

7

2013

N/A

N/A

peritonitis

Catheter removal

Converted to HD

CAM, TIPC/CVA, VCM, GM (N/A)

13

2012

13 months

IgAN, DM, HTN

ESI

Catheter removal

Converted to HD, and reinserted a new PD catheter after 5 months

CAM (28 weeks), AMK (8 weeks), LVFX (4 weeks), MEPM (2 weeks)

13

2012

> 60 months

crescentic mesangioproliferative gromerulonephritis

ESI, peritonitis

Catheter removal

Converted to HD

AMK (8 weeks), CFX (28 weeks), MEPM (4 weeks)

13

2012

49 months

DMN

ESI,

Continued PD without catheter removal

Died after 16 months because of peritonitis

CAM (14 weeks), AMK (14 weeks),

13

2012

19 months

MPA

ESI

Continued PD without catheter removal

Continued PD

CAM (42 weeks), AMK (8 weeks)

13

2012

3 months

obstructive uropathy

peritonitis

Catheter removal

Converted to HD, and reinserted a new PD catheter after 9 months

AMK (4 weeks), AZM (6 weeks), MFLX (20 weeks)

13

2012

> 20 months

DMN

ESI, TI

Catheter removal

Converted to HD

CAM (11 weeks), MEPM (5 weeks)

14

2012

N/A

CGN

ESI, TI

Catheter removal

Converted to HD, and reinserted a new PD catheter after 4 weeks

CAM (14 weeks), IPM (5 weeks), DOXY (9 weeks)

15

2012

60 months

N/A

ESI, peritonitis

Catheter removal

Converted to HD

CAM (8 weeks), AMK (8 weeks)

15

2012

12 months

DMN

peritonitis

Catheter removal

Converted to HD

CAM (3 months)

6

2011

18 months

DM, IHD, HTN

ESI, TI

Catheter removal

Converted to HD

CAM (6 weeks)

6

2011

21 months

DM, HTN

ESI

Untreated

Paliative care

Untreated

6

2011

40 months

HTN

peritonitis

Catheter removal

Converted to HD

CAM (4 weeks), AMK (4 weeks)

6

2011

6 months

DM

ESI, peritonitis

Catheter removal

Converted to HD

CAM (3 months), CPFX (3 months)

6

2011

36 months

DM, IHD, HTN

ESI, TI, peritonitis

Catheter removal

Converted to HD

CAM, AMK (N/A)

6

2011

40 months

DM, IHD, HTN

ESI, TI

Catheter removal

Converted to HD, and reinserted a new PD catheter after 6 weeks

CAM (6 weeks), EB (2 weeks)

6

2011

46 months

DM, IHD, HTN

ESI, TI, peritonitis

Catheter removal

Converted to HD, and reinserted a new PD catheter after 3 months

CAM (3 months), AMK (6 weeks)

16

2007

11 months

CGN

ESI, TI

Simultaneous catheter removal and reinsertion

Removed the reinserted catheter because of developing peritonitis, and converted to HD

CAM (7 weeks), AMK (3 weeks), CPFX (3 weeks)

17

2005

N/A

SLE

ESI

Catheter removal

Converted to HD, and reinserted a new PD catheter after 3 months

CAM (6 weeks), AMK (6 weeks)

18

1998

12 months

DMN

peritonitis

Catheter removal

Converted to HD

CAM (3 months), AMK (3 months)

AMK amikacin, AZM azithromycin, CAM clarithromycin, CEZ cefazolin, CFX cefoxitin, CGN chronic glomerulonephritis, CPFX ciprofloxacin, DM diabetes mellitus, DMN diabetic nephropathy, DOXY doxycycline, EB ethambutol, ESI exit-site infection, F female, FRPM faropenem, GM gentamicin, HD hemodialysis, HTN hypertension, IgAN immunoglobulin A nephropathy, IHD ischemic heart disease, IPM imipenem, LVFX levofloxacin, M male, MEPM meropenem, MFIPC flucloxacillin, MFLX moxifloxacin, MPA microscopic polyangitis, N/A not available, PD peritonealdialysis, RFP rifampicin, SLE systemic lupus erythematosus, TGC tigecycline, TI tunnel infection, TIPC/CVA ticarcillin/clavulanic acid, VCM vancomycin,

An official American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) statement has recommended that surgery is generally indicated for cases of M. abscessus infection with extensive disease, abscess formation, or where antibiotic therapy is difficult. Thus, removal of foreign bodies (e.g., percutaneous catheters) is important and probably essential to recovery [20]. Among the 28 reported cases, 24 cases (85.7%) involved catheter removal during treatment, and only 4 cases (14.5%) did not involve catheter removal. Moreover, only 2 patients (7.1%) continued PD during antibiotic treatment or debridement without removing the catheter, and both cases involved ESI or TI without peritonitis. Two other patients died, with 1 patient dying 16 months after developing peritonitis [13], and the other selecting palliative care after developing enterococcal and candidal peritonitis [6]. Among the 24 cases with catheter removal, 23 cases were converted to HD and 1 case was shifted to palliative care. Three cases with ESI or TI but no peritonitis underwent simultaneous removal and reinsertion of the catheter, although all cases were refractory, required subsequent catheter removal, and were ultimately converted to HD. Six other cases received a second catheter after resolution of the peritoneal symptoms and were converted back to PD, with a reinsertion interval of 4 weeks to 9 months. Among the 23 cases with catheter removal and conversion to HD, 1 patient died after 8 months because of renal hemorrhage and retroperitoneal infection, and a second patient died after 5 months because of peritoneal sclerosis [7, 11].

In the studies mentioned above, all patients with peritonitis had their catheters removed. Only two cases of ESI or TI continued PD without progressing to peritonitis, without the removal of the catheter. Hence, there is a possibility to continue PD without catheter removal if M. abscessus is identified early and before progressing to peritonitis, provided appropriate antibiotic therapy has started. In this context, acid-fast staining should have been performed to rapidly detect Mycobacterium spp., although Song et al. reported that 33.3% of cases involved smear-negative disease [4]. Therefore, in many cases there might be a prolonged delay to identify M. abscessus, and the ESI or TI can progress to refractory peritonitis. In our case, MRCNS was detected in the swab culture at the initial visit, but it was thought to be a skin indigenous bacterium from the course. Acid-fast staining of the dialysis effluent was negative at the time of peritonitis diagnosis, but gram-positive bacilli were detected on repeated cultures, and M. abscessus was identified. In addition to our case, at least 3 of the 28 reported cases of PD-associated infection caused by M. abscessus were initially positive for Gram-positive bacilli, and were diagnosed as M. abscessus at a later date. Therefore, we believe that the detection of gram-positive bacillus should alert the clinician to the possible presence of Mycobacterium spp., and lead to early identification regardless of acid-fast staining results. In the ISPD guidelines, there is no algorithm to follow if gram-positive bacilli are present, but it is considered to be an important finding in the differentiation of Mycobacterium spp.

Many cases may require a prolonged interval to identify M. abscessus, and the ESI or TI can progress to refractory peritonitis. Simultaneous reinsertion of a new PD catheter may prolong ESI or TI caused by M. abscessus, even in the absence of peritonitis. Thus, catheter reinsertion should only be attempted after the original catheter has been removed and the peritoneal symptoms have completely resolved.

Antibiotic susceptibility testing is recommended in similar cases, as M. abscessus has variable susceptibility, although it is uniformly resistant to the standard antituberculous agents [21, 22, 23]. According to the ATS/IDSA, serious skin, soft tissue, and bone infections caused by M. abscessus should be treated using clarithromycin or azithromycin plus parenteral medication, such as amikacin, cefoxitin, or imipenem [20]. The macrolides are the only oral agents that are reliably active against M. abscessus in vitro [22, 24], and the most active parenteral agent is amikacin. However, acquired mutational resistance to clarithromycin and amikacin can occur, because M. abscessus only has a single copy of the related gene. The isolate in the present case was sensitive to clarithromycin and imipenem, but was resistant to amikacin. Although the susceptibilities from the reported cases are unclear, 23 cases (82.1%) were treated using clarithromycin and 15 cases (53.6%) were treated using amikacin, with various durations of antibiotic therapy. The ATS/IDSA suggests that a minimum treatment of 4 months is necessary to provide a high likelihood of cure for serious disease, and 6 months of therapy is recommended for bone infections [20, 25]. Thus, although the precise treatment duration remains unclear, several months are likely necessary to successfully treat PD-associated infection. However, due to limited sensitivity to antibiotics and their side effects, 11 cases eventually shifted to monotherapy treatment, of which 9 were oral clarithromycin monotherapy. There was no relapse of infection in 9 cases, and 4 of them resumed PD, supporting the possibility to control infection even with monotherapy treatment. Although clarithromycin is the only effective antibiotic at present, single agent treatment is not desirable, due to the possible induction of resistant bacteria. Even in the ISPD guidelines, there is no statement on the selection of antibiotics and treatment period after sensitivity is determined. Therefore, further studies are necessary to elucidate the optimal treatment regime.

There was a delay in the identification of M. abscessus in this case, which we believe was due to the fact that there was a small number of bacteria present at the onset of peritonitis that led to late growth of bacteria in the media, but it is possible that the detection of gram-positive bacillus was effective for the early identification of Mycobacterium spp.. Thus, the simultaneous reinsertion of a new PD catheter might have prolonged the ESI and influenced the progression to peritonitis. Therefore, NTM should be considered as a possible causative organism in cases of refractory ESI or TI. Furthermore, catheter removal is usually necessary in cases of M. abscessus PD-associated infection, and reinsertion should only be attempted after complete resolution of peritoneal symptoms after several months of antibiotic therapy. M. abscessus is the most resistant bacterium among acid-fast bacteria, and further consideration is needed regarding the selection and treatment period of antibiotics.

Notes

Acknowledgements

Not applicable.

Funding

This study was not supported financially by any public, private or non-for-profit organization.

Availability of data and materials

Further clinical data and images to support this case are available from the corresponding author upon reasonable request.

Authors’ contributions

RY was the treating physician and wrote the bulk of the manuscript. KT, KY, ME and TI also treated the patient and critically revised the manuscript. HS performed urologic intervention and was the consultant for this case. RY, MK, SF and AY contributed to data collection, analysis and interpretation. All authors have read and approved the final manuscript.

Author’s information

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Piraino B, Bernardini J, Sorkin M. The influence of peritoneal catheter exit-site infections on peritonitis, tunnel infections, and catheter loss in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1986;8:436–40.CrossRefGoogle Scholar
  2. 2.
    van Diepen AT, Tomlinson GA, Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. Clin J Am Soc Nephrol. 2012;7:1266–71.CrossRefGoogle Scholar
  3. 3.
    Szeto CC, Leung CB, Chow KM. Change in bacterial aetiology of peritoneal dialysis-related peritonitis over 10 years: experience from a Centre in South-East Asia. Clin Microbiol Infect. 2005;11:837–9.CrossRefGoogle Scholar
  4. 4.
    Song Y, Wu J, Yan H, Chen J. Peritoneal dialysis-associated nontuberculous mycobacterium peritonitis: a systematic review of reported cases. Nephrol Dial Transplant. 2012;27:1639–44.CrossRefGoogle Scholar
  5. 5.
    Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36:481–508.CrossRefGoogle Scholar
  6. 6.
    Renaud CJ, Subramanian S, Tambyah PA, Lee EJ. The clinical course of rapidly growing nontuberculous mycobacterial peritoneal dialysis infections in Asians: a case series and literature review. Nephrology (Carlton). 2011;16:174–9.CrossRefGoogle Scholar
  7. 7.
    Jiang SH, Roberts DM, Clayton PA, Jardine M. Non-tuberculous mycobacterial PD peritonitis in Australia. Int Urol Nephrol. 2013;45:1423–8.CrossRefGoogle Scholar
  8. 8.
    Kusunoki S, Ezaki T, Tamesada M. Application of colorimetric microdilution plate hybridization for rapid genetic identification of 22 Mycobacterium species. J Clin Microbiol. 1991;29:1596–603.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Mooren VHJF, Bleeker MWP, van Ingen J, Hermans MHA, Wever PC. Disseminated Mycobacterium abscessus infection in a peritoneal dialysis patient. IDCases. 2017;9:6–7.CrossRefGoogle Scholar
  10. 10.
    Hibi A, Kasugai T, Kamiya K. Peritoneal dialysis-associated catheter infection caused by Mycobacterium abscessus in an elderly patient who was successfully treated with catheter removal. CEN Case Rep. 2017;6:175–9.CrossRefGoogle Scholar
  11. 11.
    Yang TK, Lee JJ, Lu PL, Kuo HT, Kuo MC, Chen HC. Peritoneal Dialysis-associated peritonitis caused by Mycobacterium abscessus. Perit Dial Int. 2015;35:369–71.CrossRefGoogle Scholar
  12. 12.
    Tsai SF. Catheter related infection due to Mycobacterium abscessus in a patient under peritoneal dialysis. Ther Apher Dial. 2013;17:349–50.CrossRefGoogle Scholar
  13. 13.
    Lo MW, Mak SK, Wong YY, et al. Atypical mycobacterial exit-site infection and peritonitis in peritoneal dialysis patients on prophylactic exit-site gentamicin cream. Perit Dial Int. 2013;33:267–72.CrossRefGoogle Scholar
  14. 14.
    Jo A, Ishibashi Y, Hirohama D, Takara Y, Kume H, Fujita T. Early surgical intervention may prevent peritonitis in cases with Tenckhoff catheter infection by nontuberculous mycobacterium. Perit Dial Int. 2012;32:227–9.CrossRefGoogle Scholar
  15. 15.
    Siddiqi N, Sheikh I. Peritonitis caused by Mycobacterium abscesses in patients on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl. 2012;23:321–4.PubMedGoogle Scholar
  16. 16.
    Kameyama H, Mori Y, Kimura T, et al. A case report of Mycobacterium abscessus peritonitis in a peritoneal dialysis patient. Ther Apher Dial. 2007;11:449–51.CrossRefGoogle Scholar
  17. 17.
    Ellis EN, Schutze GE, Wheeler JG. Nontuberculous mycobacterial exit-site infection and abscess in a peritoneal dialysis patient. A case report and review of the literature. Pediatr Nephrol. 2005;20:1016–8.CrossRefGoogle Scholar
  18. 18.
    Slagle KM, Oblack DL. Mycobacterium abscessus peritonitis: a case report. Clin Lab Sci. 1998;11:206–8.PubMedGoogle Scholar
  19. 19.
    Pierce DA, Williamson JC, Mauck VS, Russell GB, Palavecino E, Burkart JM. The effect on peritoneal dialysis pathogens of changing topical antibiotic prophylaxis. Perit Dial Int. 2012;32:525–30.CrossRefGoogle Scholar
  20. 20.
    Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.CrossRefGoogle Scholar
  21. 21.
    Stone MS, Wallace RJ Jr, Swenson JM, Thornsberry C, Christensen LA. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics. Antimicrob Agents Chemother. 1983;24:486–93.CrossRefGoogle Scholar
  22. 22.
    Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985;28:807–11.CrossRefGoogle Scholar
  23. 23.
    Brown BA, Wallace RJ Jr, Onyi GO, De Rosas V, Wallace RJ 3rd. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992;36:180–184.Google Scholar
  24. 24.
    Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. Fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1991;35:773–5.CrossRefGoogle Scholar
  25. 25.
    Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis. 1985;152:500–14.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Ryuichi Yoshimura
    • 1
  • Miharu Kawanishi
    • 1
  • Shungo Fujii
    • 1
  • Aska Yamauchi
    • 1
  • Kentaro Takase
    • 1
  • Kaori Yoshikane
    • 1
  • Masahiro Egawa
    • 1
  • Hiroaki Shiina
    • 2
  • Takafumi Ito
    • 1
  1. 1.Division of NephrologyShimane University HospitalIzumoJapan
  2. 2.Department of UrologyShimane University Faculty of MedicineIzumoJapan

Personalised recommendations